Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(3)

Detailed Status

Withdrawn2
Recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

withdrawn233%
recruiting233%
completed117%
terminated117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

NCT07312292
recruitingphase_2

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

NCT06555133
terminatedphase_1

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
completed

Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

NCT04771988
withdrawnphase_1

Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer

NCT02288507
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07312292Phase 2

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

Recruiting
NCT06555133Phase 2

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

Recruiting
NCT04108481Phase 1

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

Terminated
NCT04771988

Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

Completed
NCT02288507Phase 1

Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer

Withdrawn
NCT03307603Phase 1

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
6